Markets:

Overview

News

Currencies

International

Treasuries

Pfizer (NY:PFE)

27.80 -0.32 (-1.14%)

Official Closing Price Updated: 7:00 PM EDT, Oct 2, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

Headline News about Pfizer

< Previous 1 2 3 4 5 6 7 8 9

...

99 100 Next >

Bristol Myers Squibb Now Trades at Only 9.4X Forward Earnings -- Is This Value Stock a Buy? ↗

Today 3:20 EDT

Bristol Myers Squibb isn't a growth stock, but it may offer something to bargain hunters and dividend seekers.

Via The Motley Fool

Topics Intellectual Property

Better Pharmaceuticals ETF: VanEck's PPH vs. Invesco PJP ↗

October 02, 2026

VanEck offers lower costs and double the dividend yield, while Invesco delivered stronger 1-year returns with more balanced holdings.

Via The Motley Fool

Topics ETFs

Novo Nordisk vs. Pfizer: Which Healthcare Stock Is a Better Buy in 2026? ↗

October 02, 2026

Novo Nordisk boasts a 33% net margin and fortress balance sheet, while Pfizer trades cheaper but faces major patent cliffs through 2030.

Via The Motley Fool

Topics Intellectual Property

Pfizer (NYSE:PFE) Nears Breakout as Technical Strength and Setup Quality Reach Top Marks ↗

September 24, 2026

Via Chartmill

Pfizer Is Down 34% Over the Last 5 Years. Here's Why Its 6% Dividend Yield Might Finally Be Worth the Risk. ↗

October 02, 2026

Pfizer has been going through a period of transition.

Via The Motley Fool

Topics Earnings

Kevin Warsh's Inflation Stance Makes These Cheap Dividend Stocks Look a Lot More Attractive ↗

October 01, 2026

Inflation is running hot, and the Fed is raising interest rates, but consumers aren't likely to pull back on the products these companies sell.

Via The Motley Fool

Topics Economy

Regeneron, Sanofi Expand Alliance in Deal Worth Up to $8 Billion ↗

October 01, 2026

Regeneron Pharmaceuticals (NASDAQ:REGN) and Sanofi said they are expanding their long-running collaboration to develop and commercialize next-generation medicines for type 2 inflammatory diseases,...

Via MarketBeat

Topics ETFs

With the Market Flashing Warning Signs Not Seen Since the Dot-Com Bust, Is Pfizer's 6% Yield a Safe Haven or a Trap? ↗

September 29, 2026

While Pfizer's dividend looks like a trap, its strong balance sheet and low valuation make it safer.

Via The Motley Fool

Topics Intellectual Property World Trade

Here Are My Top 2 High-Yield Healthcare Stocks to Buy Now ↗

September 29, 2026

Pfizer and Bristol Myers Squibb pair big dividends with growing drug pipelines, a rare combination for income-focused pharma investors.

Via The Motley Fool

Topics Intellectual Property

18 of 21 Analysts Still Think Alnylam Stock Is a Buy. Here's Why They're Right. ↗

September 28, 2026

Wall Street expects an even bigger rebound for this beaten-down biotech stock.

Via The Motley Fool

5 Dividend Stocks Yielding Over 5% With Fortress Financial Profiles to Buy Now ↗

September 27, 2026

These high-yielding stocks offer very durable dividends.

Via The Motley Fool

Kevin Warsh Just Signaled Higher-for-Longer Rates. Here's What That Means for Big Pharma Dividend Stocks. ↗

September 27, 2026

Pharmaceutical company share prices may suffer, but probably not by as much as some might fear.

Via The Motley Fool

Topics Bonds Economy

D-Wave Quantum vs. QuantumScape: Which Moonshot Tech Stock Is a Better Buy in 2026? ↗

September 26, 2026

Both companies are years from commercial scale and burning cash to get there. The difference is in how long each can keep going.

Via The Motley Fool

AbbVie vs. Pfizer: Which Healthcare Stock Makes Your Portfolio Healthier in 2026? ↗

September 25, 2026

AbbVie pivots toward newer immunology drugs while Pfizer leans on acquisitions to offset pandemic decline, but their financial profiles and valuations tell starkly different stories.

Via The Motley Fool

Topics Intellectual Property

These S&P500 stocks are the most active in today's session ↗

September 24, 2026

Via Chartmill

Treasury Yields Hit a 19-Year High—These 2 Bond ETFs Offer Monthly Income ↗

September 24, 2026

As bond yields climb amid record U.S. debt, Vanguard's BSV and VCIT ETFs offer TTM yields of about 4% and 5%, respectively, with potential for rising monthly distributions.

Via MarketBeat

Topics Bonds ETFs

Bristol Myers Squibb vs. Pfizer: Which Healthcare Stock Is a Better Buy in 2026? ↗

September 24, 2026

Both face patent cliffs and pay generous dividends, but only one of them can tell you where its next wave of growth is coming from.

Via The Motley Fool

Topics Intellectual Property Regulatory Compliance

Viking's Obesity Edge May Be Staying Power, Not Weight Loss ↗

September 23, 2026

Viking Therapeutics shares jumped 36% after VK2735 maintenance data showed patients kept most weight loss on less frequent dosing, though Phase 3 results and commercial funding remain unresolved.

Via MarketBeat

Regeneron Highlights EYLEA HD Momentum, Dupixent Growth and Pipeline Catalysts ↗

September 23, 2026

Regeneron Pharmaceuticals (NASDAQ:REGN) executives highlighted continued growth across key marketed products, a broad late-stage pipeline and an ongoing focus on science-driven business development...

Via MarketBeat

Topics ETFs

Pfizer, Kraft, and UPS All Yield More Than 6%. Which of These Dividend Stocks Is the Safest Option Today? ↗

September 23, 2026

These are among the highest-yielding stocks on the S&P 500.

Via The Motley Fool

Topics Stocks

Should Dividend Investors Buy Pfizer Stock for Its High Yield or Invest in Eli Lilly for Its Dividend Growth? ↗

September 22, 2026

When investing in a dividend stock, it's important to consider not just the yield, but also the potential for dividend growth and overall risk.

Via The Motley Fool

Topics Economy

Pfizer Refocuses Growth Strategy as New Products Offset COVID Decline ↗

September 22, 2026

Pfizer (NYSE:PFE) has rebuilt its commercial model around newer and acquired products while reducing exposure to its COVID-19 franchise, according to Alexandre de Germay, the company’s chief...

Via MarketBeat

Topics Intellectual Property

AbbVie vs. Pfizer: Which Dividend Stock Is the Better Buy in September? ↗

September 22, 2026

These companies are committed to rewarding shareholders.

Via The Motley Fool

2 Large-Cap Stocks to Keep an Eye On and 1 Facing Headwinds

September 22, 2026

Large-cap stocks have the power to shape entire industries thanks to their size and widespread influence. With such vast footprints, however, finding new are...

Via StockStory

CoreWeave vs. D-Wave Quantum: Is the AI Giant or the Quantum Computer Upstart the Better Stock Investment? ↗

September 21, 2026

Both are high-growth bets on unproven cutting-edge technologies.

Via The Motley Fool

Topics Artificial Intelligence

1 Mid-Cap Stock with Exciting Potential and 2 We Turn Down

September 21, 2026

Many investors pay attention to mid-cap stocks because they have established business models and expansive market opportunities. However, their paths to beco...

Via StockStory

Pfizer Says Its Biggest Headwinds Are Finally Easing. Does That Change the Story for This Ultra-High-Yield Dividend Stock? ↗

September 20, 2026

Pfizer's rebound is well underway.

Via The Motley Fool

Topics Intellectual Property World Trade

Wall Street's Bull Case for Bristol Myers Squibb Is Getting Louder ↗

September 20, 2026

The company's strong pipeline and newer approved drugs should be enough to allay patent expiration concerns.

Via The Motley Fool

Topics Intellectual Property

Is Pfizer an Excellent Dividend Stock to Buy? ↗

September 19, 2026

Pfizer has a history of developing treatments that generate billions in sales.

Via The Motley Fool

3 Dividend Stocks to Buy and Hold for 10 Years ↗

September 18, 2026

They have a knack for increasing their dividends even when facing challenges.

Via The Motley Fool

Topics Intellectual Property

< Previous 1 2 3 4 5 6 7 8 9

...

99 100 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.

Pfizer (NY:PFE)

Headline News about Pfizer

Starting at /week.